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Abstract
Background: Patients with dementia may have limited capacity to give informed consent to participate in clinical research.
One possible way to safeguard the patients’ interests in research is the involvement of a proxy in the recruitment process. In
Italy, the system of proxy is determined by the courts. In this study we evaluate the timing for appointment of a legal proxy
in Italy and identify predictive variables of appointment.
Methodology/Principal Findings: Subjects were recruited among the outpatients seeking medical advice for cognitive
complaints at the Centre for Research and Treatment of Cognitive Dysfunctions, University of Milan, ‘‘Luigi Sacco’’
Hospital. The Centre was participating to the AdCare Study, a no-profit randomised clinical trial coordinated by the Italian
National Institute of Health. The requirement that informed consent be given by a legal representative dramatically slowed
down the recruitment process in AdCare, which was prematurely interrupted. The Centre for Research and Treatment of
Cognitive Dysfunctions collected data on the timing required to appoint the legal representatives. Patients diagnosed with
dementia and their caregivers were provided information on the Italian law on legal agency (law 6/2004). At each scheduled
check-up the caregiver was asked whether she/he had applied to appoint a legal proxy for the patient and the time interval
between the presentation of the law, the registration of the application at the law court chancellery and the sentence of
appointment was registered. The study involved 169 demented patients. Seventy-eight patients (46.2%) applied to appoint
a legal proxy. These subjects were usually younger, had been suffering from dementia for a longer time, had less than two
children and made more use of memantine. The mean interval time between the presentation of the law and the patients’
application to the law court chancellery was two months. The mean interval time between the patient’s application to the
law court chancellery and the sentence of appointment was four months.
Conclusions/Significance: In Italy the requirement that legal representatives be appointed by the courts slows down
subjects’ participation in research. Other procedures for legal agency of the incapacitated patients may be adopted, taking
as examples other EU countries’ systems.
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Introduction
People with dementia often lack mental capacity and subse-
quently need assistance in their decision making. Research
involving individuals with compromised mental ability can be
ethically challenging as the lack of capacity may limit their ability
to give free and informed consent.
The need to adopt special cautions in research involving
individuals with compromised capacity has been highlighted by
the most relevant declarations on research ethics, like the
Nuremberg Code and the Declaration of Helsinki.
The Nuremberg Code of 1947 [1], adopted a restrictive
approach towards participation of incompetent patients in
research, stating that: ‘‘The voluntary consent of the human
subject is absolutely essential. This means that the person involved
should have legal capacity to give consent’’ (point 1).
In the 1964 version of the Declaration of Helsinki [2] the
possibility of ‘‘surrogate’’ or ‘‘proxy’’ consent overcame the
‘‘preclusion’’ from participation in research of incompetent
patients: ‘‘In case of legal incompetence, informed consent should
be obtained from the legal guardian in accordance with national
legislation’’ (point 11).
Thereafter, following the first version of the Declaration of
Helsinki, other relevant declarations on research ethics have
confirmed the acceptability of surrogate or proxy consent thus
sanctioning the ethical acceptability of participation of incompe-
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to these subjects.
The 2008 version of the Declaration of Helsinki states that
potential research subjects who are incompetent ‘‘must not be
included in a research study that has no likelihood of benefit for
them unless it is intended to promote the health of the population
represented by the potential subject, the research cannot instead
be performed with competent persons, and the research entails
only minimal risk and minimal burden’’ (point 27).
Moreover, ‘‘When a potential research subject who is deemed
incompetent is able to give assent to decisions about participation
in research, the physician must seek that assent in addition to the
consent of the legally authorized representative. The potential
subject’s dissent should be respected’’ (point 28).
These principles have been adopted by all national legislation in
western countries.
However, while the protection afforded to potential research
participants who lack capacity has received recognition through
legislation and ethical debate, the practical aspect of recruiting and
retaining such participants in research presents a number of
challenges.
One main problem in dementia research is the evaluation of
the patient’s capacity and, when the individual is deemed
competent, the requirement that he or she expresses a valid
consent to participate. To give valid consent the potential
participant should understand and retain relevant information,
weigh the information, make a decision and communicate the
decision [3]. In the context of clinical trials the information
should include the purpose of the trial, the trial procedures, the
risks and benefits of participation. Potential participants should
understand the concept of equipoise which provides the ethical
basis for the conduction of a clinical trial, placebo (if used), and
randomization.
According to some authors if participants were required to
understand all of this information, dementia research would
become ‘‘harder to conduct’’ [4] or it would cease entirely,
restricting the continuing development of a much needed area of
research [5].
As indicated by the Declaration of Helsinki, one possible way to
meet the ethical requirements of informed consent is to safeguard
the potential participants interests through the use of proxy
consent in the recruitment process. At present, the majority of
Alzheimer’s Disease (AD) research is conducted with ‘‘double
consent’’, that is, by obtaining consent from both the patient and a
proxy who is typically a family caregiver.
The practice of obtaining surrogate consent however can vary
according to differences in national legislation. In particular, in
some countries, including Italy, the system of proxy is determined
by the courts - a procedure which is not necessarily required for
the recognition of a proxy in other countries.
In the European Union (EU) a common legal framework for the
inclusion and protection in research of adults who lack capacity is
set up by the Directive 2001/20/EC [6], also known as the
‘‘Clinical Trials Directive’’ (hereinafter the Directive).
To ensure legal protection to incapacitated participants in
research the Directive requires the written consent of the
participant’s legal representative.
However, according to the Directive ‘‘The notion of legal
representative refers back to existing national law and conse-
quently may include natural or legal persons, an authority and/or
a body provided for by national law’’(introduction, point 5).
National implementation of the Directive hence raises distinct
issues which reflect the legal, cultural, political and socio-economic
background within each member state.
To compare the national legal framework of some EU member
states regarding the inclusion and protection in research of
incapacitated participants we retrieved national laws using the
European Forum for Good Clinical Practice (EFGCP) Report on
‘‘The Procedure for the Ethical Review of Protocols for Clinical
Research Projects in the European Union’’ [7].
In particular, we analysed the national laws on clinical trials
which are written in English, French or Spanish or for which an
English translation is available.
Some countries have legislation that is specific to an
incapacitated participant’s involvement in research while in other
countries the proxy provision falls from legislation on health and
welfare more broadly.
Several legislation provide that an individual is able to appoint a
representative prior to the onset of incapacity (e.g. Belgium,
France, Italy, U.K. and Germany).
In all of the analysed legislation: Belgium [8], Denmark [9],
Finland [10], France [11], Germany [12], Ireland [13,14], Italy
[15,16], the Netherlands [17], Spain [18] and the UK [19,20] a
relative is allowed to take on the role of proxy.
However, only in Germany and Italy the system of proxy is
determined by the courts - a procedure which is not necessarily
required for the recognition of a proxy in other member states.
In Belgium, the Netherlands, Finland and Spain a more
pragmatic procedure has been adopted for proxy consent in
research. This system describes a cascade of measures aimed to
legitimately arrive at a consent that reflects the individual’s
presumed will, going from the authorised legal representative to a
hierarchy of family members.
In France a similar system for legal agency is in place. However,
if according to the ethics committee the research imposes serious
risks to the participant’s private life or bodily integrity, authorisa-
tion to participation must be given by the tutelary judge.
In Ireland an incapacitated person may only participate in a
clinical trial if written and signed consent is given by a person,
independent from the trial, who in the opinion of the ethics
committee is able to give a decision on such a participation.
In Denmark, if an adult is permanently incapacitated consent
must be given by the nearest relative (or legal representative) and
the person’s general practitioner (GP).
Also in the UK, if it is not reasonably practicable to contact an
adult’s legal representative then the doctor primarily responsible for
the medical treatment of the individual, or a person nominated by the
relevant health care provider,can act as legal representative, providing
they have no connection with the conduct of the clinical trial [19].
The different ways of obtaining surrogate consent for subject’s
participation in research in the EU countries may have an impact
on countries ‘‘attractiveness’’ for dementia research.
For example, one may suppose that countries where courts are
not involved in the appointment of a patient’s proxy are more
attractive for dementia research, as courts involvement may slow
down the process of appointment of the proxy and hence of
obtainment of the informed consent. However the available data,
even if they are quite limited, do not confirm this hypothesis.
According to clinicaltrials.gov many clinical trials on dementia are
being conducted in Europe (Figure 1).
It is to note that in Germany, where the patient’s legal proxy
must be appointed by the courts, the number of clinical trials
involving patients with dementia is high.
Recently in Germany a law was published, amending the Civil
Code, regulating sensitive issues like the value of advanced
directives and surrogate consent in the care of incompetent
patients. The law specifies the value and the limits of the decisions
of the ‘‘authorised representatives’’ in the care of the incompetent
Dementia Research in Italy
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authorised representative [21].
Unluckily we did not retrieve detailed information on the
German system for legal agency of persons with compromised
capacity, which apparently allows a good level of participation in
research of the patients with dementia.
This is not the case for Italy.
In Italy relatives are not ‘‘legally authorized representatives’’
and cannot give informed consent in clinical practice nor in
medical research. Legal agency is mediated by the courts but at
present very few patients have appointed a legal representative.
This may be due to the fact that, until recently, legal agency for
incompetent persons was synonymous of debarment.
In 2004 a law has changed the civil code, and in place of the
traditional institutions of guardianship and tutelage, which
completely deprived persons of their legal rights, legal agency is
now focused on care and assistance [16]. The new legal entity is a
‘‘carer’’ (in Italian: ‘‘amministratore di sostegno’’) and is
appointed by the tutelary judge, found in every magistrate’s
court. The law provides for a hierarchy of family members who
can be appointed as legal proxy going from the beneficiary’s
spouse to his or her partner, father or mother, son or daughter,
brother or sister, and other persons who are close to the patient.
Nomination is inexpensive, the patient can directly apply for it
and he/she can indicate his or her legal proxy prior to the onset
of incapacity. Also relatives, neighbours and healthcare profes-
sionals can apply for appointment. Persons working in the
healthcare or social services who are directly involved in the care
of the person, when needed, must invite the tutelary judge to
appoint a legal proxy for the patient. However, they themselves
Figure 1. Interventional Studies on dementia in Europe (Available: www.clinicaltrials.gov; accessed 2010 May 3).
doi:10.1371/journal.pone.0011150.g001
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the patient.
The legal proxy must warrant the patient’s desires in treatment
decisions.
In the act of appointment, the judge must specify all actions that
the legal proxy will be able to do for the person, which may
include the care of his or her health and the right to give informed
consent, as well as the management of his or her financial affairs.
The kind and number of powers and duties assigned to the legal
proxy do not determine the length of the process of appointment
which, according to the law, should be completed in 60 days.
However, in very urgent cases the tutelary judge may intervene
with an accelerated procedure.
Theoretically, the law is easily applicable. The patient or his or
her relatives do not need a lawyer’s assistance to enforce it, they do
not have to pay any money (apart from a J 8 revenue stamp) but
must present several documents to the tutelary judge among which
a medical certificate and a birth certificate which can only be
obtained in the patient’s common of birth.
Since the publication of the law 6/2004 many Italian courts
have experienced an exponential increase in demand of
appointment of the legal proxies for the persons who need it [22].
For this reason we hypothesise that the requirement that
informed consent for an incapacitated subject’s participation to a
research be given by a legal representative appointed by the courts
slows down the recruitment process in research thus complicating
the conduction of dementia research in Italy.
In this study we want to verify how does the Italian law 6/2004
work and more precisely:
1. Evaluate the timing and procedure for the appointment of a
patient’s legal proxy according to the law 6/2004;
2. Identify the predictive variables of the appointment of the legal
proxy according to the law 6/2004.
Methods
Subjects were recruited among the outpatients seeking medical
advice for cognitive complaints at the Centre for Research and
Treatment of Cognitive Dysfunctions of the Department of
Neurology, University of Milan, ‘‘Luigi Sacco’’ Hospital.
The centre was participating to the AdCare Study, a no-profit
randomised clinical trial coordinated by the Italian National
Institute of Health on the efficacy and safety of antipsychotic drugs
in the treatment of behavioural and psychological disturbances in
patients with Alzheimer’s disease (AD) (the AdCare Study,
Eudract code: 2008-000243-33).
The AdCare study was approved by the ethics committee of the
Italian National Institute of Health and by the local research ethics
committees (RECs) of the 19 clinical centres which participated in
the study, including Luigi Sacco Hospital’s REC.
The procedure to obtain informed consent in AdCare was
quite elaborated. First, subject’s competence was evaluated by
means of the Mini Mental State Examination (MMSE). If the
subject’s score was $20, then he or she underwent four
additional neuropsychological tests: the Babcock Recall Story
Test, the Controlled Oral Word Association (letters and
categories) and the Trail making test. If the subject’s score to
the four tests was higher than the established cut-offs the subject
was deemed able to give informed consent and was informed of
the study characteristics: its purposes, design, possible risks and
benefits of participation, voluntariness of participation and the
right to withdraw [23].
After presenting the study some checking questions were made
to the participant to assess his or her level of comprehension of the
information received [3]. The questions were:
What do you believe is wrong with your health now?
Do you believe that you need some kind of treatment?
What is treatment likely to do for you?
What makes you believe it will have that effect?
What do you believe will happen if you are not treated?
Why do you think your doctor has (or I have) recommended this
treatment?
Have you decided whether to follow your doctor’s (or my)
recommendation for treatment? Can you tell me what that
decision is?
(if no decision) What is making it hard for you to decide?
If the subject’s MMSE score was ,20, adjusted for age and
education, or if the subject’s score to the other four tests was lower
than the established cut-offs, the subject was deemed unable to
give informed consent and consent had to be given by a legally
authorised representative.
The requirement that informed consent be given by a legally
authorised representative dramatically slowed down the recruit-
ment process in AdCare. The Centre for Research and Treatment
of Cognitive Dysfunctions at the Milano Sacco Hospital decided to
collect data on the timing required to appoint a legal represen-
tative for subjects-participants to document the real difficulty of
the process.
Patients included in this survey were enrolled from September
2007 to October 2009. All patients underwent a diagnostic work-
up, routinely applied in the outpatient clinic for evaluation of
patients with cognitive impairment, which included an interview
with the patient and an informant, medical, psychiatric and
neurological examinations, routine blood screening, extensive
neuropsychological examination and structural neuroimaging.
Two experienced neurologists (FC and LM) collected informa-
tion concerning cognitive and behavioural symptoms (psychosis,
agitation, sleep disorders) and assigned Basic [24] and Instrumen-
tal [25] Activities of Daily Living (BADL, IADL) and Clinical
Dementia Rating (CDR) [26] scores. The information for the
BADL, IADL and CDR was collected according to the subject
and an informant. Global cognitive functioning was assessed using
the MMSE [27].
Dementia was diagnosed according to DSM IV criteria [28],
Alzheimer’s Disease (AD) according to NINCDS-ADRDA criteria
[29], Lewy Body Dementia (LBD) according to McKeith criteria
[30], Frontotemporal dementia (FTD) according to Lund and
Manchester criteria [31] and vascular dementia (VaD) according
to NINDS-AIREN criteria [32].
Patients were all receiving standard treatments for dementia,
including cholinesterase inhibitors (AchE-Is), memantine, antipsy-
chotics, antidepressants and benzodiazepine.
All the consecutive patients receiving a diagnosis of dementia
and their caregiver were included in the study and were asked
whether they were acquainted with the law 6/2004, regarding the
possibility of appointing a legal proxy for the patient. If they were
not acquainted with the law 6/2004 a neurologist (FC or LM) and
a psychologist (SFI) provided information on it.
The time dedicated to describe the law 6/2004 to each patient
and family member was about one hour, to be added to the usual
visit time.
The neurologist illustrated the clinical reasons why a person
with dementia may present limitations of the decisional capacity,
which may render necessary the appointment of a legal proxy. For
example, language disturbs may affect the capacity to understand
relevant information or to express one’s wishes; memory disturbs
Dementia Research in Italy
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informed choice in clinical practice and in research.
Successively, the neurologist illustrated some clinical contexts in
which the informed consent of a legal proxy would be required
(e.g. invasive procedures and surgical acts, prescription of drugs for
off label use, participation in clinical research). To end, the
neurologist described the context of clinical research (the AdCare
study) for which the informed consent of a legal proxy was
required, underlining the importance of the study and its relevance
for public health.
The accompanying family members were given time to read an
informative sheet which resumed the law 6/2004 and the
informed consent form of the AdCare study. The family members
could keep a copy of the documents to discuss participation to the
AdCare study with their general practitioner (GP) or with other
family members.
Successively, during the same encounter, the psychologist
described technical aspects of the law (for example the possibility
that the tutelary judge extended the field of legal agency to the
management of the patient’s properties and to the duty to be
accountable for the patient’s expenses) and bureaucratic aspects
(court’s address, court’s opening times, documents to be presented
to the tutelary judge).
Moreover, the psychologist made herself available, also by
giving her number of mobile phone, to answer to every question
which may raise during the visit or thereafter, and to help the
patient and the caregiver(s) in filling the court’s forms. Every
patient and caregiver was left the time to discuss these issues with
their GP or with other persons whom they trusted.
Finally, the patient was provided with a disease certificate and
was recommended to start up the procedure of appointment of the
legal proxy specifying that the legal proxy must ‘‘keep contacts
with the health authorities and give informed consent to surgical
acts, medical treatments and participation in clinical research’’.
During the following visits, the same neurologist and the same
psychologist made themselves available to give other information
and to listen to any patient’s or caregiver’s doubts.
At each scheduled check-up the caregiver(s) was/were asked
whether he or she had applied to appoint a legal proxy and, if yes,
progresses of the procedure were checked.
If the patient or the caregiver(s) had applied to appoint the legal
proxy the following information were gathered:
1. date of the medical visit and presentation of the law;
2. date of registration of the application at the law court
chancellery;
3. date of the sentence for the appointment of the legal proxy;
4. legal proxy’s name and degree of relationship, if any, with the
beneficiary;
5. legal proxy’s powers;
6. legal proxy’s duties.
If no legal proxy was appointed, we asked to the patient and the
caregiver(s) why they decided not to apply for appointment.
This survey was a non interventional study, and the approval of
a research ethics committee was not required by the Italian
legislation. Hence, the approval of the local research ethics
committee was not sought.
Nearly all the recruited patients were not able to give consent
and the informed consent of a caregiver who is not a legally
authorised representatives has no legal value in Italy. Therefore,
informed consent was not required to subjects nor to their ‘‘non
legally authorised’’ caregivers to participate in this survey. Indeed,
for many patients the main ‘‘outcome’’ of the survey was the
appointment of a legally authorised representative who will be able
to give informed consent in future studies.
Results
The study involved 172 demented patients, affected by AD
(n=133; 77%), VaD (n=15; 9%) LBD (n=12; 7%), FTD (n=3;
2%) and unspecified dementia (n=9; 5%), respectively.
Only 3 patients (1.7%) and their relatives were already
acquainted with the law 6/2004 and had autonomously applied
to appoint a legal proxy (Figure 2).
Seventy-eight patients out of 169 (46.2%) applied for appoint-
ment. Nearly two months passed between the date of the medical
visit in which the neurologist and the psychologist presented the
law to the patient and his or her caregiver(s) and the date in which
the patient and the caregiver(s) applied to the law court
chancellery (median time 57 days).
Fifty-five applications out of 78 (70.5%) ended up with
appointment. An average time of four months passed between
registration of the application to the law court chancellery and the
sentence of appointment of the legal proxy (median time 121
days). In all these cases the tutelary judge appointed a relative: a
son or a daughter, 63.6% (35/55); the spouse, 27.3% (15/55);
others relatives (two nephews, one sister, one son-in-law, one sister-
in-law), 9.1% (5/55).
Details on the cohort characteristics and description of the two
subgroups of patients (those for whom a legal proxy was appointed
and those for whom it was not appointed) are reported in figure 2.
Table 1 shows the demographic and clinical characteristics of
the 169 patients included in the cohort and the two subgroups of
patients. We found only two statistically significant differences
between the two groups: the subjects who started up the procedure
of appointment had been suffering from dementia for a longer
time (2.362.2 versus 1.661.8 yrs; p=0.02) and made more use of
memantine (15.4% vs 4.4%; p=0.02) than those who did not start
up the procedure of appointment.
The multivariate analysis (Figure 3) shows that patients with less
than two children had a higher probability to start up the
procedure of appointment (OR 2.20; 95% CI 1.02–4.76) as
compared to patients who had more than two children. The
subjects who started up the procedure of appointment were
younger (OR 2.40; 95% CI 1.03–5.53) and made more use of
memantine (OR 4.93; 95% CI 1.01–24.12) than those who did not
start up the procedure. Some patients made more use of AChE-Is,
but the difference was not statistically significant (OR 2.14; 95%
CI 0.89–5.18).
The presence of a care worker in the patient’s home slightly
increased the chances of appointment of the legal proxy.
We could retrieve information on the legal proxy’s powers in 38
of 55 sentences (69%) of the tutelary judge. The most frequent
power recognised to the legal proxy was ‘‘to keep contacts with the
health authorities and to give informed consent to surgical acts,
medical treatments and clinical research’’ (36/38; 95%), followed
by ‘‘to manage the patient’s property’’ (33/38; 87%), ‘‘to decide
for the patient’s living arrangements (choosing between a home
and a nursing home or a residential care home)’’ (31/38; 82%), ‘‘to
keep contacts with the tributary authority and other public bodies’’
(25/38; 66%).
We could retrieve information on the legal proxy’s duties in 33
of 55 sentences (60%) of the tutelary judge. The most frequent
duties assigned to the legal proxy were: ‘‘to give an account to the
tutelary judge on the patient’s property management’’ (28/33;
85%) and ‘‘to give an account to the tutelary judge on the patient’s
general conditions’’ (24/33; 73%).
Dementia Research in Italy
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a legal proxy. Of these, 70 (76.9%) gave no specific motivations for
not appointing the legal proxy. The more frequent reasons cited
for not appointing a legal proxy were the following:
a) disagreements among relatives about who should be the legal
proxy and when to start up the procedure of appointment
(9.9%);
b) negative advice of GPs or other relevant figures on the
opportunity to appoint a legal proxy (6.6%);
c) relatives’ fear of economic implications (i.e. fear that the
legal proxy may take economic advantage of his or her
position, or take control on the patient’s fiscal situation,
personal estate and legacies) (5.5%);
d) relatives’ fear of psychological relapses on the part of the
patient (worries about upsetting him or her) (1.1%).
Discussion
There is consensus over the fact that adults who lack capacity
should be supported by proxy consent when involved in research.
However, the question of who can act in this way, the extent of
their authority and how they are appointed differs between
countries. These inconsistencies raise questions as to which
procedures best support the subject’s interests; protecting them
from unethical and illegal procedures, but also allowing them to
potentially reap the benefits of the outcomes of the research,
namely beneficial treatments.
The requirement that a legal representative support potential
participants in their decision to participate to a clinical trial should
ensure protection of research participants. Unfortunately, howev-
er, in Italy the requirement that the legal representative be
appointed by the courts may impede a subject’s participation in
research for several reasons.
Within the context of a family the need to appoint one single
person as the subject’s legal representative may cause embarrass-
ment and conflicts among family members.
In fact, in our study group the number of sons and daughters
was a predictive variable of ‘‘non appointment’’ of the legal proxy.
The more cited reasons for not appointing a legal proxy were the
impossibility to achieve an agreement among relatives, followed by
the relatives’ fear that the legal proxy may take advantage of his
position.
This worry seems partially justified since, even when appoint-
ment was required to allow the proxy ‘‘to keep contacts with the
health authorities and to give informed consent’’, in 87% of cases
the tutelary judge also conferred him/her the power ‘‘to manage
the patient’s property’’.
Further, even in a peaceful family arrangement, relatives may
perceive the need to appoint a legal representative as a
Figure 2. Patients applying and not applying to appoint a legal proxy and the time required for appointment.
doi:10.1371/journal.pone.0011150.g002
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may be reluctant to make difficult decisions on behalf of the
potential participant, and so may postpone the decision to take on
this role.
Finally, some families may perceive courts to be a stigmatizing
place, thought primarily for criminal settings [33]. As such they
may be reluctant to attend court as part of the process of
appointing a legal proxy.
We can hypothesise that, due to the complexity and multiple
implications of the procedure of appointment of the legal
proxy, only some ‘‘privileged’’ categories of patients succeed in
achieving it.
The results of our study partly support this view. We found
indeed that the probability of appointing a legal proxy was
associated with the younger patient’s age (OR 2.40; 95% CI 1.03–
5.55) and the longer duration of the patient’s disease (2.362.2
versus 1.661.8 yrs; p=0.02). This would suggest that the legal
procedure is more often carried on by patients who have received
an early diagnosis of dementia. Precocity of the diagnosis may be
indicative of the patients’ and relatives’ stronger attention to the
symptoms of dementia as well as their prompter access to the
healthcare services. Prompt access to the healthcare services may
be related to the patients’ and relatives’ more confident access to
other public services, including the law courts. This is compatible
with the slightly higher educational level of the patients who
started up the procedure of appointment of a legal proxy.
Our data also suggest that the procedure of appointment was
carried out by the patients who had a more stable and lasting
relationship with our clinical centre.
This view seems supported by the statistical association among
the appointment of a legal proxy and the patient’s use of
memantine (OR 4.93; 95% CI 1.01–24.12) and a quasi-significant
association with the patient’s use of AChE-Is (OR 2.14; 95% CI
0.89–5.18). Indeed, when the AdCare study was started, in the
Lombardy region memantine was gratuitously distributed from
clinical centres participating to a project [34] coordinated by the
Centre for Research and Treatment on Cognitive Dysfunctions,
‘‘L. Sacco’’ Hospital [35]. Since July 2005 the patients who were
taking memantine had been entering three-monthly to the centre
to verify the efficacy and tolerability of the treatment and to
receive memantine for the following three months. The patients
who were taking cholinesterase inhibitors had been entering to the
centre every six-month as provided by the Italian regulation on the
reimbursement of these treatments. Hence, we can presume that
the patients and relatives who had more promptly appointed a
legal proxy for the patient were the patients who had a strong and
fiduciary relation with the neurologist, as they were stably related
to the centre by the system for reimbursement of pharmacological
Table 1. Baseline patient characteristics.
All patients n. 169 Application for the appointment of a legal proxy p
Yes (n. 78) No (n. 91)
Mean age (years) 7967.2 7967.7 8066.7 0.18
Female (%) 66.3 67.9 64.8 0.67
Mean duration of disease (years) 1.962.0 2.362.2 1.661.8 0.02
Alzheimer’s disease (%) 77.5 80.8 74.7 0.35
Education (years) 6.764.2 7.264.2 6.364.3 0.18
Number of children 2.061.5 1.861.4 2.161.5 0.11
Civil status (% Married) 54.4 56.4 52.7 0.63
Caregiver (%)
Son/daughter
Spouse
Other family member
Care worker
Other
56.2
37.9
2.4
0.6
3.0
56.4
37.2
2.6
-
3.8
56.0
38.5
2.2
1.1
2.2
0.86
Presence of a care worker (%) 36.7 42.3 31.9 0.16
Mean MMSE score 16.865.8 16.465.3 17.166.1 0.37
Mean ADL score 3.661.9 3.461.9 3.761.9 0.36
Mean IADL score 1.961.8 1.961.8 2.061.8 0.76
Use of antipsychotic drugs (%) 13.6 16.7 11.0 0.28
Use of AChE-Is (%) 47.3 52.6 42.9 0.21
Use of antidepressant drugs (%) 27.2 26.9 27.5 0.94
Use of benzodiazepine (%) 16.0 14.1 17.6 0.54
Use of memantine (%) 9.5 15.4 4.4 0.02
Aggression (%) 41.4 43.6 39.6 0.60
Psychosis (%) 28.4 25.6 30.8 0.46
Insomnia (%) 20.7 16.7 24.2 0.23
MMSE: Mini Mental State Examination.
ADL: Activity of Daily Living.
IADL: Instrumental Activity of Daily Living.
AChE-Is: Cholinesterase Inhibitors.
doi:10.1371/journal.pone.0011150.t001
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the Centre with:
N more frequent scheduled visits;
N direct reservation with the centre (instead of reservation by the
regional call-centre)
N availability of a mobile phone number to call at any time to
notify adverse drug reactions.
This ‘‘preferential’’ treatment may have contributed to reinforce
the trusting relationship among patients, their caregivers and the
centre thus determining a more favourable attitude towards the
suggestions of the centre’s staff, including the suggestion to provide
legal agency to the patient.
It is to note that the appointment of a legal proxy would have
had no advantage nor any disadvantage for these patients as
regarding the possibility to receive a beneficial treatment.
As regarding reasons for not appointing a legal proxy, besides
relatives’ reluctance to start up the procedure, we identified
another obstacle, which is the time required to complete all the
procedure once started. In fact, our data show that the median
time required to carry out all the proceeding is on average twofold
(median time 121 days) than that previewed by the law (60 days).
Hence, the times required by the courts to appoint a legal
representative may not be synchronised with the times required for
an individual’s participation in research.
For all these reasons the system which is actually in place in Italy
seems far from effective in balancing the needs of protection of
subjects and the need of rapid times for subject’s enrolment in
research.
Indeed, the difficulties in recruiting patients in AdCare, mostly
due to complexities in the informed consent procedure, deter-
mined the anticipated interruption of the trial.
The data that we provide here refer to one of the most active
centres participating to the AdCare study, and one related to a
well functioning court. Following the same procedure for informed
consent, many other centres participating to the AdCare study
didn’t succeed in recruiting not even one patient.
If we should think how to change the system in place we could
take example from other EU countries systems. For example, the
pragmatic approach adopted in the Belgian, Dutch, French or
Spanish legislation, providing proxy consent from a hierarchy of
family members when a legal representative is not available, seem
more encouraging towards clinical research than appointing a
Figure 3. Predictive variables of appointment: results of the logistic regression analysis.
doi:10.1371/journal.pone.0011150.g003
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Results of our study show indeed that, conformingly to the law, the
legal proxies appointed by the courts are patient’s relatives in
100% of the cases. Thus, from a pragmatic point of view, the
adoption of a juridical proceeding to confirm what naturally
happens among the patient’s families may seem redundant.
However, relatives’ consent may be less protective towards
subjects in that less control would be given to the procedure of
their appointment. Nevertheless, we know of no data supporting
the idea that more control, for example through the involvement
of courts, allows better protection towards potential research
participants.
Another possibility would be to empower the offices of the
tutelary judges in courts to fasten the times required to appoint the
legal proxies. Empowering courts however would require to invest
more financial and human resources in the Italian court system.
Moreover, this would not solve the other obstacle that we observed
in our study that is relatives’ reluctance to appoint a legal proxy.
Another way to ensure protection to research participants would
be to empower the role of GPs as some legislation provides. The
role of ethics committees may also be strengthened. In the
Netherlands a central committee for medical research reviews the
protocols for certain types of research (without direct benefit)
involving people who are unable to give informed consent [17].
Also in the UK, the ethical review of research protocols involving
incapacitated adults is made by specialised ethics committees [36].
Doctors and ethics committees are likely to have the expertise to
judge whether or not a proposed trial is in the best interest of
participant. However, doctors and ethics committees might have
potential conflict of interests with their colleagues or with the drug
industry [37,38] and select the legal representative who is more
favourable to patient’s involvement in research.
On the contrary, courts may have a more neutral and impartial
approach towards appointing the proxy which better represents
the patient’s interests, but the involvement of courts, as we have
demonstrated, slows down the process of appointment.
Additional protections may be important to safeguard partic-
ipants’ welfare. Nevertheless, the role played by a potential
participant’s autonomy and the principle of informed consent are
irreplaceable in the ethics of clinical research.
More studies should be devoted to the practice of proxy consent
and to questions regarding the extent to which formal designation
of a proxy does guarantee a more accurate representation of a
participant’s wishes. Divergent views emerge in this respect. Some
studies show that elder persons and persons at risk of developing
Alzheimer disease are generally supportive of surrogate consent for
participation in research [39,40]. Other studies show that often
there is only fair agreement between what a proxy thinks a patient
would decide and what the patient actually decides in his or her
care [41,42].
Ideally a proxy should have a clear understanding of a potential
participant’s wishes with respect to their involvement in research.
To enhance understanding it will be important that doctors,
patients and their caregivers discuss the possible evolution of the
disease and any potential opportunities for participation in a
clinical trial at an early stage of the disease’s development [43].
This will allow the proxy to be more prepared should such an
opportunity arise in the future. This ’learning and preparation’
can be achieved through the relationships among potential
participants, proxies, doctors and other healthcare providers but
also in the wider arena of public debate.
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